Cholesterol Animations, Lipoprotein Animations, Statins Animations

Peripheral Fat Breakdown Undermined By Bad Cholesterol
The so called bad cholesterol (LDL) inhibits the breakdown of fat in cells of peripheral deposits, according to a study from the Swedish medical university Karolinska Institutet. The discovery reveals a novel function of LDL as a regulator of fat turnover besides its well-established detrimental effects in promoting atherosclerosis. The study, which is a collaboration of two research groups at Karolinska Institutet, is published in the open-access journal PLoS ONE.

Metabolex Announces Positive Results From Phase 2 Clinical Trial Of MBX-8025
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 clinical trial of MBX-8025. A summary of the results was presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) on November 1, 2008. MBX-8025 is an oral drug candidate that is being evaluated for the treatment of dyslipidemia.

Soy Protein's Ability To Lower Cholesterol Confirmed, Possible Mechanism Of Action Described
Solae, a leader in soy protein innovation and technology, unveiled a new study today at the 8th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment. A new meta-analysis confirms that soy protein consumption can lead to a meaningful and significant reduction in blood cholesterol levels.

Colesevelam HCl Lowered LDL Cholesterol In Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Daiichi Sankyo, Inc. (DSI), announced today that results from the pivotal study supporting the use of colesevelam HCl in pediatric patients with heterozygous familial hypercholesterolemia (heFH), were presented for the first time at the American Heart Association's (AHA) Annual Scientific Sessions 2008.

The Influence Of Statin Medications On Prostate-specific Antigen Levels
UroToday.com - According to a report by Dr. Robert J. Hamilton and associates that appears in the November 5, 2008 issue of the Journal of the National Cancer Institute, statin use lowers PSA levels, and as a result may confound the detection of prostate cancer (CaP) in these patients. Statins are lipid-lowering agents in widespread use in the US. Several reports suggest that men on statins have a reduction in the risk of advanced CaP that ranges from 25% to 75%.

GP Survey Shows Concerns Over Tolerability Of Higher Dose Statins
According to the results of a new survey of 500 GPs across the UK, many GPs have concerns about the tolerability profile of higher doses of statins that are significant enough to affect their prescribing decisions.

Damage Inflicted During Cardiac Attacks More Widespread Than Previously Thought, MSU Researchers Find
Cholesterol crystals released in the bloodstream during a cardiac attack or stroke can damage artery linings much further away from the site of the attack, leaving survivors at greater risk than previously thought.

Health Risks For Large, Retired Athletes May Be Lowered By Staying Active
Study highlights: Retired NFL players have fewer heart disease risk factors overall, but higher cholesterol and glucose levels. Physical activity may have prevented the development of higher rates of diabetes or greater amounts of atherosclerosis. Since today's players are 50 percent larger than 25 years ago, further study is needed on whether current players are at greater risk for cardiovascular events or death, researchers said.

Statin Reduces Heart Attack, Stroke Rates In Patients With Normal Cholesterol But Elevated C-Reactive Protein
New data from the landmark ATHENA trial showed that dronedarone significantly reduced the incidence and total duration of hospital stays among patients with atrial fibrillation/atrial flutter (AF/AFL). This post-hoc analysis was presented at the 2008 American Heart Association Scientific Sessions in New Orleans, Louisiana. In this new analysis, dronedarone significantly reduced the total number of hospital days by 28 percent (p

Colesevelam HCl Lowered LDL Cholesterol In Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Daiichi Sankyo, Inc. (DSI), announced that results from the pivotal study supporting the use of colesevelam HCl in pediatric patients with heterozygous familial hypercholesterolemia (heFH), were presented for the first time at the American Heart Association's (AHA) Annual Scientific Sessions 2008.

Crestor Can Reduce Risk For Cardiovascular Events In Patients With High Levels Of Protein, Study Finds
The cholesterol medication Crestor, manufactured by AstraZeneca, can reduce by about half the risk for heart attack, stroke and death among patients who do not have high cholesterol levels but tested positive for high levels of a protein linked with increased risk for heart attack, according to a study presented Sunday at the annual meeting of the

VAP(R) Cholesterol Test Helps Researchers Identify Treatment Effects Of Combination Therapy
Using the VAP Cholesterol Test from Atherotech, Inc., investigators led by Michel Farnier M.D., of Point Medical, Rond Point de la Nation, Dijon, France, have reported beneficial changes in lipoprotein subclasses and LDL particle size using combination therapy. The information could be helpful to physicians because of the known association between abnormal lipoprotein subfractions and increased cardiovascular risk in patients with mixed hyperlipidemia.

CRESTOR Demonstrates Dramatic CV Risk Reduction In A Large Statin Outcomes Study
New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p

Industry-Sponsored Research Agreement To Advance Heart-Healthy Research
Brandeis University has announced a multi-year $1 million sponsored research agreement with Smart Balance Inc. through its wholly owned subsidiary, the maker of Smart Balance® buttery spread and other low-fat and fat-free foods that help lower cholesterol through a patented blend of natural vegetable oils. In addition, Brandeis and Smart Balance have entered into a collaboration and license to develop a second-generation heart-healthy fat for Smart Balance.

Atherotech To Exhibit VAP(R) Cholesterol Test At American Heart Association Scientific Sessions 2008
Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP(R) Cholesterol Test in booth No. 2918 at the American Heart Association Scientific Sessions 2008. The annual meeting takes place Nov. 8-12 at the Ernest N. Morial Convention Center in New Orleans. Atherotech representatives will be available to discuss the VAP Cholesterol Test during regular exhibit hours on October 9, 10 and 11 in booth No.